Literature DB >> 28679093

PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.

Christopher Melani1, Ajay Major2, Jeffrey Schowinsky2, Mark Roschewski1, Stefania Pittaluga1, Elaine S Jaffe1, Svetlana D Pack1, Zied Abdullaev1, Mark A Ahlman3, Jennifer J Kwak2, Rustain Morgan2, Rachel Rabinovitch2, Zenggang Pan2, Bradley M Haverkos2, Jonathan A Gutman2, Daniel A Pollyea2, Clayton A Smith2, Wyndham H Wilson4, Manali Kamdar2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28679093      PMCID： PMC5628739          DOI： 10.1056/NEJMc1704767

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  A prospective study of mediastinal gray-zone lymphoma.

Authors:  Wyndham H Wilson; Stefania Pittaluga; Alina Nicolae; Kevin Camphausen; Margaret Shovlin; Seth M Steinberg; Mark Roschewski; Louis M Staudt; Elaine S Jaffe; Kieron Dunleavy
Journal:  Blood       Date:  2014-07-14       Impact factor: 22.113

2.  Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.

Authors:  Franziska C Eberle; Itziar Salaverria; Christian Steidl; Thomas A Summers; Stefania Pittaluga; Susana Ben Neriah; Jaime Rodriguez-Canales; Liqiang Xi; Kris Ylaya; David Liewehr; Kieron Dunleavy; Wyndham H Wilson; Stephen M Hewitt; Mark Raffeld; Randy D Gascoyne; Reiner Siebert; Elaine S Jaffe
Journal:  Mod Pathol       Date:  2011-08-05       Impact factor: 7.842

3.  Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.

Authors:  Alexandra Traverse-Glehen; Stefania Pittaluga; Philippe Gaulard; Lynn Sorbara; Miguel A Alonso; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2005-11       Impact factor: 6.394

4.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

5.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544
  5 in total
  16 in total

Review 1.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

Review 2.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

Review 3.  Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.

Authors:  Arnab Ghosh; Ioannis Politikos; Miguel-Angel Perales
Journal:  Curr Opin Oncol       Date:  2017-11       Impact factor: 3.645

Review 4.  Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.

Authors:  Reid W Merryman; Philippe Armand; Kyle T Wright; Scott J Rodig
Journal:  Blood Adv       Date:  2017-12-12

5.  Gene expression profiling of gray zone lymphoma.

Authors:  Clémentine Sarkozy; Lauren Chong; Katsuyoshi Takata; Elizabeth A Chavez; Tomoko Miyata-Takata; Gerben Duns; Adèle Telenius; Merrill Boyle; Graham W Slack; Camille Laurent; Pedro Farinha; Thierry J Molina; Christiane Copie-Bergman; Diane Damotte; Gilles A Salles; Anja Mottok; Kerry J Savage; David W Scott; Alexandra Traverse-Glehen; Christian Steidl
Journal:  Blood Adv       Date:  2020-06-09

Review 6.  Immunotherapy of lymphomas.

Authors:  Stephen M Ansell; Yi Lin
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

7.  Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma.

Authors:  Koji Takaishi; Tomoya Muto; Naoya Mimura; Jun Takiguchi; Yuhei Nagao; Nagisa Oshima-Hasegawa; Shokichi Tsukamoto; Yusuke Takeda; Shio Mitsukawa; Masahiro Takeuchi; Chikako Ohwada; Satoshi Ota; Tohru Iseki; Chiaki Nakaseko; Emiko Sakaida
Journal:  Int J Hematol       Date:  2018-05-21       Impact factor: 2.490

Review 8.  Immunomodulators in Lymphoma.

Authors:  Theodora Anagnostou; Stephen M Ansell
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

9.  Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma- Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma.

Authors:  Zsófia Simon; Bálint Virga; László Pinczés; Gábor Méhes; Zsófia Miltényi; Sándor Barna; Roxana Szabó; Árpád Illés
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

Review 10.  Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.

Authors:  Bei Hu; Ryan Jacobs; Nilanjan Ghosh
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 4.213
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.